Highlights
Market Capitalization | 1.9M |
Book Value | - $0.66 |
Earnings Per Share (EPS) | 73.96 |
PE Ratio | 0.01 |
PEG Ratio | 0.0 |
Wall Street Target Price | 500.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -127.37% |
Return On Equity TTM | -798.16% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | 73.96 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -6.87 |
EPS Estimate Next Year | -4.7 |
EPS Estimate Current Quarter | -1.62 |
EPS Estimate Next Quarter | -1.3 |
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on PBLA
Decreasing Revenue
Revenue is down for the last 2 quarters, -1.58M → -1.63M (in $), with an average decrease of 3.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -6.47M → -7.12M (in $), with an average decrease of 10.0% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 160.8%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 286.5%
Discover More
Keyarch Acquisition Corp
$0.34
+0.45%
Connexa Sports Technologies Inc
$0.34
+0.45%
Us Value Etf
$0.34
+0.45%
First Wave Biopharma Inc
$0.34
+0.45%
Global X Msci Next Emerging
$0.34
+0.45%
Fat Projects Acquisition Corp
$0.34
+0.45%
Capital Link Global Fintech
$0.34
+0.45%
Applied Uv Inc
$0.34
+0.45%
Columbia International Esg Equity Income Etf
$0.34
+0.45%